JP2019501896A - 抗菌化合物としての置換ベンザジノン - Google Patents

抗菌化合物としての置換ベンザジノン Download PDF

Info

Publication number
JP2019501896A
JP2019501896A JP2018529622A JP2018529622A JP2019501896A JP 2019501896 A JP2019501896 A JP 2019501896A JP 2018529622 A JP2018529622 A JP 2018529622A JP 2018529622 A JP2018529622 A JP 2018529622A JP 2019501896 A JP2019501896 A JP 2019501896A
Authority
JP
Japan
Prior art keywords
branched
linear
heterocyclyl
straight
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018529622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501896A5 (cg-RX-API-DMAC7.html
Inventor
チー、チン
デニス、テオティコ、ポールハウス
ジャレッド、スプレッツトーザー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2019501896A publication Critical patent/JP2019501896A/ja
Publication of JP2019501896A5 publication Critical patent/JP2019501896A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2018529622A 2015-12-08 2016-12-08 抗菌化合物としての置換ベンザジノン Pending JP2019501896A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264628P 2015-12-08 2015-12-08
US62/264,628 2015-12-08
PCT/IB2016/057451 WO2017098440A1 (en) 2015-12-08 2016-12-08 Substituted benzazinones as antibacterial compounds

Publications (2)

Publication Number Publication Date
JP2019501896A true JP2019501896A (ja) 2019-01-24
JP2019501896A5 JP2019501896A5 (cg-RX-API-DMAC7.html) 2020-01-23

Family

ID=57680436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018529622A Pending JP2019501896A (ja) 2015-12-08 2016-12-08 抗菌化合物としての置換ベンザジノン

Country Status (10)

Country Link
US (2) US10781184B2 (cg-RX-API-DMAC7.html)
EP (1) EP3386950A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019501896A (cg-RX-API-DMAC7.html)
KR (1) KR20180088456A (cg-RX-API-DMAC7.html)
CN (1) CN108368053A (cg-RX-API-DMAC7.html)
AU (2) AU2016367510A1 (cg-RX-API-DMAC7.html)
BR (1) BR112018011670A2 (cg-RX-API-DMAC7.html)
CA (1) CA3007653A1 (cg-RX-API-DMAC7.html)
RU (1) RU2018124788A (cg-RX-API-DMAC7.html)
WO (1) WO2017098440A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
MX379690B (es) * 2016-09-28 2025-03-11 Dong A St Co Ltd Derivados de tetrahidropiridina y su uso como agentes antibacterianos
CN109593066B (zh) * 2018-12-21 2020-06-19 上海交通大学 一种用于治疗肠道细菌感染的叶酸拮抗剂及其制备与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530372A (ja) * 2007-06-12 2010-09-09 アカオゲン，インコーポレーテッド 抗菌剤
JP2013514345A (ja) * 2009-12-16 2013-04-25 ファイザー・インク 抗菌剤として有用なｎ−結合型ヒドロキサム酸誘導体
WO2015173329A1 (en) * 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG2012000667A (en) * 2003-01-08 2015-03-30 Univ Washington Antibacterial agents
WO2015164458A1 (en) * 2014-04-22 2015-10-29 Novartis Ag Isoxazoline hydroxamic acid derivatives as lpxc inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530372A (ja) * 2007-06-12 2010-09-09 アカオゲン，インコーポレーテッド 抗菌剤
JP2013514345A (ja) * 2009-12-16 2013-04-25 ファイザー・インク 抗菌剤として有用なｎ−結合型ヒドロキサム酸誘導体
WO2015173329A1 (en) * 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [ONLINE] RETRIEVED FROM STN, vol. 検索日：2020年10月20日, JPN7020003994, pages 08 - 2015, ISSN: 0004534235 *
NING GAO; ET AL: "OVEREXPRESSION OF PSEUDOMONAS AERUGINOSA LPXC WITH ITS INHIBITORS IN AN ACRB-DEFICIENT 以下備考", PROTEIN EXPRESSION AND PURIFICATION, vol. 104, JPN5018008684, 18 September 2014 (2014-09-18), CA, pages 57 - 64, ISSN: 0004534234 *

Also Published As

Publication number Publication date
CA3007653A1 (en) 2017-06-15
EP3386950A1 (en) 2018-10-17
US20210053926A1 (en) 2021-02-25
RU2018124788A3 (cg-RX-API-DMAC7.html) 2020-03-18
KR20180088456A (ko) 2018-08-03
US20180362474A1 (en) 2018-12-20
AU2016367510A1 (en) 2018-06-07
RU2018124788A (ru) 2020-01-15
BR112018011670A2 (pt) 2018-11-27
AU2019271952A1 (en) 2019-12-19
US10781184B2 (en) 2020-09-22
CN108368053A (zh) 2018-08-03
WO2017098440A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
JP6387360B2 (ja) 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
KR102824962B1 (ko) 헤테로시클릭 rip1 억제 화합물
ES2652648T3 (es) Moduladores P2X7
US20210053926A1 (en) Substituted benzazinones as antibacterial compounds
CN114401964B (zh) 一类具有brd4抑制活性的化合物、其制备方法及用途
EA035499B1 (ru) Новые ингибиторы глутаминазы
US10239873B2 (en) 7-azaindole or 4,7-diazaindole derivatives as IKKϵ epsilon and TBK1 inhibitor and pharmaceutical composition comprising same
TW201609736A (zh) （６Ｓ，９ａＳ）－Ｎ－苄基－６－［（４－羥基苯基）甲基］－４，７－二氧－８－（｛６－［３－（哌－１－基）四氫吖唉－１－基］吡啶－２－基｝甲基）－２－（丙－２－烯－１－基）－八氫－１Ｈ－吡并［２，１－ｃ］［１，２，４］三－１－甲醯胺化合物
JP7253086B2 (ja) アミノピリジン誘導体およびそれらの選択的ａｌｋ－２阻害剤としての使用
JP6250667B2 (ja) 新しい抗菌化合物
CA3200620A1 (en) Aromatic heterocyclic compound, and pharmaceutical composition and application thereof
CN107540659A (zh) 四氢异喹啉类化合物、其制备方法、药物组合物及其用途
CN111718332B (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
JP7235859B2 (ja) 新規なチアゾール誘導体及びその薬学的に許容される塩
KR20220075335A (ko) 항균 화합물
JP2023502279A (ja) Ｃｐｓ１を阻害するためのピペラジン化合物
TW202409011A (zh) 人類呼吸道融合病毒及間質肺病毒抑制劑
WO2025237891A1 (en) Quinoline-2-carboxamide derivatives as rad51 inhibitors for the treatment of cancer
HK40072682A (en) Pyridopyrimdinone cdk2/4/6 inhibitors
WO2022214519A1 (en) Antibacterial compounds
CN120359224A (zh) 取代的杂环化合物衍生物及其制药用途
HK40047684A (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
HK40002986A (en) Pyridopyrimdinone cdk2/4/6 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210625